306934-87-2

Basic information

• Product Name: 6-Fluoro-4H-1,3-benzodioxine-8-carbaldehyde
• Synonyms: 6-FLUORO-4H-1,3-BENZODIOXINE-8-CARBALDEHYDE;6-FLUORO-1,3-BENZODIOXENE-8-CARBALDEHYDE;6-Fluoro-4H-1,3-benzodioxine-8-carboxaldehyde;6-fluoro-2,4-dihydro-1,3-benzodioxine-8-carbaldehyde;6-Fluoro-4H-benzo[d][1,3]dioxine-8-carbaldehyde
• CAS NO: 306934-87-2
• Molecular Formula: C₉H₇FO₃
• Molecular Weight: 182.15
• Mol File: 306934-87-2.mol
• Article Data: 1

Chemical Properties

• Melting Point: 113 °C
• Boiling Point: 323.051 °C at 760 mmHg
• Flash Point: 144.319 °C
• Appearance: white to light yellow crystal powder
• Density: 1.357 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-Fluoro-4H-1,3-benzodioxine-8-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Fluoro-4H-1,3-benzodioxine-8-carbaldehyde(306934-87-2)
• EPA Substance Registry System: 6-Fluoro-4H-1,3-benzodioxine-8-carbaldehyde(306934-87-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39-37/39
• Hazardous Substances Data: 306934-87-2(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powde

InChI:InChI=1/C9H7FO3/c10-8-1-6(3-11)9-7(2-8)4-12-5-13-9/h1-3H,4-5H2

Upstream product

• 131728-94-4 8-(chloromethyl)-2-fluorobenzo-1,3-dioxane 

Relevant articles and documents

INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF

The present invention relates to new compounds of formula (I) in which:X is CR4 or N; R1 is -OR5, -NHCOR6 or -NR6R7; R2 is hydrogen, Oar1 or -NHAr1 wherein Ar1 is aryl optionally substituted with one or more of R8, -OR8, -NR8R9, -CONR8R9, -COOR8, -NR8COR9, -SR8, -SO2NR8R9, -NR8SO2 R9, halogen, cyano, or nitro; R3 is hydrogen or -NHAr2 wherein Ar2 is benzene optionally substituted with one or more of R8, -OR8, -NR8R9, halogen or nitro, wherein R2 and R3 is not simultaneously hydrogen; a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.